FibroGen Inc. (NASDAQ:FGEN) CEO Thomas B. Neff sold 37,798 shares of the business’s stock in a transaction that occurred on Wednesday, September 21st. The stock was sold at an average price of $21.66, for a total transaction of $818,704.68. Following the sale, the chief executive officer now directly owns 3,379,719 shares in the company, valued at approximately $73,204,713.54. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.
FibroGen Inc. (NASDAQ:FGEN) opened at 21.78 on Tuesday. The company has a 50 day moving average of $19.15 and a 200 day moving average of $18.52. FibroGen Inc. has a 1-year low of $14.38 and a 1-year high of $31.90. The firm’s market capitalization is $1.37 billion.
FibroGen (NASDAQ:FGEN) last issued its earnings results on Monday, August 8th. The biopharmaceutical company reported $0.35 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.36 by $0.01. FibroGen had a negative net margin of 61.90% and a negative return on equity of 48.66%. Analysts forecast that FibroGen Inc. will post ($1.25) EPS for the current year.
Separately, Credit Suisse Group AG restated a “buy” rating on shares of FibroGen in a research note on Tuesday, July 12th.
A number of hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. boosted its stake in shares of FibroGen by 8.8% in the second quarter. Vanguard Group Inc. now owns 4,220,201 shares of the biopharmaceutical company’s stock valued at $69,254,000 after buying an additional 339,735 shares during the period. Norges Bank purchased a new stake in shares of FibroGen during the fourth quarter valued at $9,821,000. American Century Companies Inc. boosted its stake in shares of FibroGen by 371.5% in the second quarter. American Century Companies Inc. now owns 230,019 shares of the biopharmaceutical company’s stock valued at $3,775,000 after buying an additional 181,235 shares during the period. State Street Corp boosted its stake in shares of FibroGen by 15.1% in the first quarter. State Street Corp now owns 1,330,809 shares of the biopharmaceutical company’s stock valued at $28,335,000 after buying an additional 174,369 shares during the period. Finally, Jacobs Levy Equity Management Inc. purchased a new stake in shares of FibroGen during the first quarter valued at $2,489,000. 49.82% of the stock is currently owned by hedge funds and other institutional investors.
FibroGen, Inc is a research-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.
Receive News & Ratings for FibroGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.